ARIScience is RESHAPING THE FUTURE OF DRUG DISCOVERY
Identifying new cures for societal diseases through AI and Quantum Chemistry (AI+QQ)
Our novel in-silico platform unites AI, quantum chemistry, computer vision and bio-chemistry to design and discover molecule compounds that interrupt disease pathways. We call this novel process: AI+QQ.
Assessed via established in vitro and in vivo assays, these small molecule compounds interrupt proteins allosterically, directly or formatively.
We are pursuing treatments for prevalent neurodegenerative, inflammatory and infectious diseases by focusing on the interruption of aberrant, overexpressed or pathogenic proteins.
We are thrilled to announce that in April of 2023 we were awarded an advanced protein impact via small molecule research contract by the United States Biomedical Advanced Research and Development Agency. In October 2024 we successfully completed this BARDA project.
Bleeding-Edge Technology
Interrupt Proteins Like Never Before
Our novel in silico quasi quantum calculation methodology combined with a unique computation-first approach and diverse, purpose-driven team of experts delivers unparalleled results. Merging traditionally disparate scientific disciplines and utilizing cutting-edge technology and methodologies allows us to efficiently iterate and refine drug candidates, leading to higher success rates and a faster time-to-societal-impact for our clients. Our leading approach and expertise have resulted in a proven track record of success, and we are dedicated to bringing advanced science driven therapeutics to patients.
Drug Discovery Process
Learn how our unique AI+QQ drug discovery process addresses the burden of disease on society. For more detailed information click here.
1
Predict and construct organic compounds that can directly or allosterically interrupt proteins in biological pathways using in silico methodology.
3
Iterate and optimize compounds using derivative molecules based on in vitro results.
.jpg)
